Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism of Aspergillus fumigatus

Area of Science:

• Medicinal Chemistry
• Antimicrobial Drug Discovery
• Mycology

Background:

• Antifungal resistance in *Aspergillus fumigatus* presents a significant global health challenge.
• Existing antifungal therapies, targeting mechanisms like ergosterol synthesis, face limitations due to emerging resistance.
• There is an urgent need for novel antifungal agents with alternative mechanisms of action.

Purpose of the Study:

• To develop and evaluate a novel prodrug strategy for antifungal therapy against *Aspergillus fumigatus*.
• To leverage pathogen-specific enzymes for the in situ generation of toxic radical species.
• To overcome existing resistance mechanisms associated with conventional antifungal drugs.

Main Methods:

• Synthesis of an alkoxyamine prodrug linked to a peptide substrate recognized by *A. fumigatus*-secreted dipeptidyl peptidase.
• Kinetic analysis to confirm prodrug stability and enzymatic activation.
• In vitro assessment of prodrug efficacy against *A. fumigatus* strains, including voriconazole-resistant isolates.

Main Results:

• The designed prodrug demonstrated stability prior to enzymatic cleavage, releasing a nitroxide and a reactive alkyl radical.
• The prodrug effectively inhibited *A. fumigatus* growth in a dose-dependent manner (42% inhibition at 10 µg/L).
• Antifungal activity was observed against both voriconazole-susceptible and resistant *A. fumigatus* strains, confirming the radical's role.

Conclusions:

• A novel chemical strategy utilizing enzyme-mediated generation of toxic radicals offers a promising approach for antifungal therapy.
• This prodrug design effectively targets *Aspergillus fumigatus*, including drug-resistant strains.
• The findings provide a timely solution to combat emerging antifungal resistance and offer a new therapeutic avenue.